Bispecific antibodies for rare EGFR mutations

Rare EGFR mutations such as exon 20 insertion changes have long been considered a therapeutic dead end in non-small cell lung cancer (NSCLC). Current data show that innovative mechanisms of action also open up clinically relevant options in NSCLC. Highly sensitive molecular diagnostics and new antibody formats are now bringing this patient group more into the focus of precision oncology.